These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 36432116

  • 1. HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
    Suk FM, Wu CY, Chiu WC, Chien CY, Chen TL, Liao YJ.
    Molecules; 2022 Nov 18; 27(22):. PubMed ID: 36432116
    [Abstract] [Full Text] [Related]

  • 2. β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
    Suk FM, Wu CY, Fang CC, Chen TL, Liao YJ.
    Biomed Pharmacother; 2023 Oct 18; 166():115293. PubMed ID: 37567069
    [Abstract] [Full Text] [Related]

  • 3. HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma.
    Wang YH, Liu CL, Chiu WC, Twu YC, Liao YJ.
    Cancers (Basel); 2019 Nov 26; 11(12):. PubMed ID: 31779269
    [Abstract] [Full Text] [Related]

  • 4. HMGCS2 promotes autophagic degradation of the amyloid-β precursor protein through ketone body-mediated mechanisms.
    Hu LT, Zhu BL, Lai YJ, Long Y, Zha JS, Hu XT, Zhang JH, Chen GJ.
    Biochem Biophys Res Commun; 2017 Apr 29; 486(2):492-498. PubMed ID: 28320515
    [Abstract] [Full Text] [Related]

  • 5. miR-107-mediated decrease of HMGCS2 indicates poor outcomes and promotes cell migration in hepatocellular carcinoma.
    Su SG, Yang M, Zhang MF, Peng QZ, Li MY, Liu LP, Bao SY.
    Int J Biochem Cell Biol; 2017 Oct 29; 91(Pt A):53-59. PubMed ID: 28867541
    [Abstract] [Full Text] [Related]

  • 6. Fasting-induced HMGCS2 expression in the kidney does not contribute to circulating ketones.
    Venable AH, Lee LE, Feola K, Santoyo J, Broomfield T, Huen SC.
    Am J Physiol Renal Physiol; 2022 Apr 01; 322(4):F460-F467. PubMed ID: 35224990
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
    Hsu CH, Weng PW, Chen MY, Yeh CT, Setiawan SA, Yadav VK, Wu ATH, Tzeng DTW, Gong JX, Yang Z, Tzeng YM.
    Chem Biol Interact; 2023 Jan 25; 370():110329. PubMed ID: 36565974
    [Abstract] [Full Text] [Related]

  • 8. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line.
    Vilà-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF.
    J Biol Chem; 2011 Jun 10; 286(23):20423-30. PubMed ID: 21502324
    [Abstract] [Full Text] [Related]

  • 9. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H, Park Y, Kim T, Kim J, Lee JS, Kim SY, Chung JI, Ko HY, Pyun JC, Kim KS, Lee M, Yun M.
    BMC Cancer; 2020 Apr 19; 20(1):332. PubMed ID: 32306906
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis.
    Li J, Li MH, Wang TT, Liu XN, Zhu XT, Dai YZ, Zhai KC, Liu YD, Lin JL, Ge RL, Sun SH, Wang F, Yuan JH.
    Br J Cancer; 2021 Sep 19; 125(6):865-876. PubMed ID: 34274945
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 15. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W, Xu B, Li Q, Jiang D, Yan S.
    Mol Med Rep; 2018 Apr 15; 17(4):6185-6193. PubMed ID: 29484394
    [Abstract] [Full Text] [Related]

  • 16. HMGCS2-Induced Autophagic Degradation of Tau Involves Ketone Body and ANKRD24.
    Hu LT, Xie XY, Zhou GF, Wen QX, Song L, Luo B, Deng XJ, Pan QL, Chen GJ.
    J Alzheimers Dis; 2023 Apr 15; 91(1):407-426. PubMed ID: 36442191
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
    Gan H, Li L, Hu X, Cai J, Hu X, Zhang H, Zhao N, Xu X, Guo H, Pang P.
    Cancer Biol Ther; 2022 Dec 31; 23(1):1-14. PubMed ID: 36310384
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic inactivation of hydroxymethylglutaryl CoA synthase reduces ketogenesis and facilitates tumor cell motility in clear cell renal carcinoma.
    Han P, Wang Y, Luo W, Lu Y, Zhou X, Yang Y, Zheng Q, Li D, Wu S, Li L, Zhang H, Zhao J, Zhang Z, Matskova L, Li P, Zhou X.
    Pathol Res Pract; 2021 Nov 31; 227():153622. PubMed ID: 34624592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.